EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Long‐term evaluation of anterior thalamic deep brain stimulation for epilepsy in the European MORE registry

Elisabeth Kaufmann iD, Jukka Peltola, Albert J Colon, Kai Lehtimäki, Milan Majtanik, Jürgen K Mai, Beata Bóné, Carla Bentes iD, Volker Coenen, Antonio Gil-Nagel iD, Antonio J Goncalves-Ferreira, Philippe Ryvlin iD und 6 weitere

Epilepsia · 2024-08 · 65 (8) · 2438-2458

DOI: 10.1111/epi.18003 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Epilepsia, online erschienen am 05.06.2024. Verfasst von Elisabeth Kaufmann und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Epilepsy Center, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Anterior Thalamic Nuclei, Deep Brain Stimulation, Drug Resistant Epilepsy, Registries. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medtronic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Short‐term outcomes of deep brain stimulation of the anterior nucleus of the thalamus (ANT‐DBS) were reported for people with drug‐resistant focal epilepsy (PwE). Because long‐term data are still scarce, the Medtronic Registry for Epilepsy (MORE) evaluated clinical routine application of ANT‐DBS.

Methods

In this multicenter registry, PwE with ANT‐DBS were followed up for safety, efficacy, and battery longevity. Follow‐up ended after 5 years or upon study closure. Clinical characteristics and stimulation settings were compared between PwE with no benefit, improvers, and responders, that is, PwE with average monthly seizure frequency reduction rates of ≥50%.

Results

Of 170 eligible PwE, 104, 62, and 49 completed the 3‐, 4‐, and 5‐year follow‐up, respectively. Most discontinuations (68%) were due to planned study closure as follow‐up beyond 2 years was optional. The 5‐year follow‐up cohort had a median seizure frequency reduction from 16 per month at baseline to 7.9 per month at 5‐year follow‐up ( p < .001), with most‐pronounced effects on focal‐to‐bilateral tonic–clonic seizures ( n = 15, 77% reduction, p = .008). At last follow‐up (median 3.5 years), 41% (69/170) of PwE were responders. Unifocal epilepsy ( p = .035) and a negative history of epilepsy surgery ( p = .002) were associated with larger average monthly seizure frequency reductions. Stimulation settings did not differ between response groups. In 179 implanted PwE, DBS‐related adverse events (AEs, n = 225) and serious AEs ( n = 75) included deterioration in epilepsy or seizure frequency/severity/type (33; 14 serious), memory/cognitive impairment (29; 3 serious), and depression (13; 4 serious). Five deaths occurred (none were ANT‐DBS related). Most AEs (76.3%) manifested within the first 2 years after implantation. Activa PC depletion ( n = 37) occurred on average after 45 months. Significance MORE provides further evidence for the long‐term application of ANT‐DBS in clinical routine practice. Although clinical benefits increased over time, side effects occurred mainly during the first 2 years. Identified outcome modifiers can help inform PwE selection and management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anterior Thalamic NucleiDeep Brain StimulationDrug Resistant EpilepsyRegistriesAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultEuropeFollow-Up StudiesTreatment Outcome

Stichwörter der Autor:innen

ANT‐DBSSANTEdrug‐resistant epilepsyneuromodulationneurostimulationpredictor of outcome

Autor:innen und Institutionen

  • Department of Neurology, Epilepsy Center, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Neurology, Tampere University and Tampere University Hospital, Tampere, Finland.
  • Academic Center for Epileptology Kempenhaeghe/Maastricht UMC+, Maastricht, The Netherlands.
  • Department of Neurosurgery, Tampere University Hospital and Tampere University, Tampere, Finland.
  • MRX-Brain GmbH, Düsseldorf, Germany.
  • Department of Informatics, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany.

ORCID-Profile: Elisabeth Kaufmann, Carla Bentes, Antonio Gil-Nagel, Philippe Ryvlin

Förderung

  • Medtronic

Zitieren

APA

Kaufmann, E., Peltola, J., Colon, A. J., Lehtimäki, K., Majtanik, M., Mai, J. K., Bóné, B., Bentes, C., Coenen, V., Gil-Nagel, A., Goncalves-Ferreira, A. J., Ryvlin, P., Taylor, R., Brionne, T. C., Gielen, F., Song, S., Boon, P., & MORE study group (2024). Long‐term evaluation of anterior thalamic deep brain stimulation for epilepsy in the European MORE registry. Epilepsia, 65(8), 2438-2458. https://doi.org/10.1111/epi.18003

Vancouver

Kaufmann E, Peltola J, Colon AJ, Lehtimäki K, Majtanik M, Mai JK, et al. Long‐term evaluation of anterior thalamic deep brain stimulation for epilepsy in the European MORE registry. Epilepsia. 2024;65(8):2438-2458. doi:10.1111/epi.18003

BibTeX
@article{Kaufmann2024,
  author = {Kaufmann, Elisabeth and Peltola, Jukka and Colon, Albert J and Lehtimäki, Kai and Majtanik, Milan and Mai, Jürgen K and Bóné, Beata and Bentes, Carla and Coenen, Volker and Gil-Nagel, Antonio and Goncalves-Ferreira, Antonio J and Ryvlin, Philippe and Taylor, Rod and Brionne, Thomas C and Gielen, Frans and Song, Shannon and Boon, Paul and MORE study group, MORE study group},
  title = {Long‐term evaluation of anterior thalamic deep brain stimulation for epilepsy in the European MORE registry},
  journal = {Epilepsia},
  year = {2024},
  volume = {65},
  number = {8},
  pages = {2438--2458},
  doi = {10.1111/epi.18003}
}
Kostenlos starten →